GlassScriptPhysician profile
Aloice O Aluoch
NPI 1245541259
$29,179.31
in general payments reported to CMS, 2019-2025
44 companies · $4,572 in 2025
The $4,572 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $2,659 · 2021: $3,827 · 2022: $5,262 · 2023: $7,350 · 2024: $4,597 · 2025: $4,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $1,620 · Education: $168 · Travel and Lodging: $69.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,662.03 |
| Consulting Fee | $1,620.00 |
| Education | $168.36 |
| Travel and Lodging | $69.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,509.54 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $5,050.00 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $4,093.50 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Horizon Therapeutics Plc | $2,254.56 | 2019-2023 | Krystexxa |
| Pfizer INC. | $1,360.77 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,351.15 | 2019-2025 | |
| Ucb, INC. | $1,044.55 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $1,041.48 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $747.02 | 2022-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $699.00 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $676.97 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $475.98 | 2020-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $369.19 | 2023-2025 | Purified Cortrophin Gel, Sovuna |
| Lilly USA, LLC | $288.10 | 2020-2023 | Taltz |
| Organon LLC | $232.92 | 2021-2025 | Renflexis, Hadlima |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $227.83 | 2019-2025 | Strensiq |
| Sanofi-Aventis U.S. LLC | $202.77 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $199.80 | 2024-2025 | Orencia |
| Kiniksa Pharmaceuticals, LTD. | $150.98 | 2021-2023 | Arcalyst |
| Genzyme Corporation | $139.92 | 2019-2024 | |
| Genentech USA, INC. | $132.66 | 2019-2025 | Gazyva, Actemra |
| Sobi, INC | $119.74 | 2023-2025 | |
| Hikma Pharmaceuticals USA | $92.55 | 2019-2021 | |
| Sandoz INC. | $65.05 | 2023-2024 | Hyrimoz |
| Currax Pharmaceuticals LLC | $60.43 | 2021-2023 | Contrave |
| Csl Behring | $52.99 | 2022-2023 | Hizentra |
| Janssen Scientific Affairs, LLC | $50.33 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.30 | 2023 | Cyltezo, Ofev |
| Zyla Life Sciences, INC. | $41.82 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $41.07 | 2024 | Arcalyst |
| Celgene Corporation | $38.60 | 2019 | |
| Fresenius Kabi USA, LLC | $37.51 | 2023-2025 | Idacio |
| Tonix Medicines, INC. | $34.35 | 2025 | Tonmya |
| Kowa Pharmaceuticals America, INC. | $34.26 | 2023 | Seglentis |
| Octapharma USA, INC. | $28.47 | 2025 | Octagam Immune Globulin (Human) |
| Invivyd INC | $27.99 | 2025 | Pemgarda |
| Mallinckrodt Enterprises LLC | $26.65 | 2019 | |
| Medexus Pharma, INC. | $24.78 | 2019-2020 | |
| Mylan Institutional INC. | $24.38 | 2023 | Hulio |
| Kci USA, INC. | $20.81 | 2023 | Prevena |
| Teva Pharmaceuticals USA, INC. | $16.32 | 2024 | Truxima |
| Merck Sharp & Dohme LLC | $15.53 | 2019 | |
| Novo Nordisk INC | $14.61 | 2025 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $14.08 | 2025 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aloice Aluoch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.